Clinical Trial Update: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Xencor's XmAb®819 is being studied in a Phase 1 trial for advanced clear cell renal cell carcinoma and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• XmAb®819

Snippet

Sponsor: Xencor, Inc. | Conditions: Clear Cell Renal Cell Carcinoma | Phase 1 | Status: RECRUITING